Refractory Thyroid Gland Carcinoma Clinical Trial
Official title:
An Open-Label, Non-Randomized, Dose Escalation, Single-Center, Investigator-Initiated Trial to Determine the Safety, Dosimetry, and Preliminary Effectiveness of 177Lu-DOTA-EB-FAPI in Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With Progressive Disease After Tyrosine Kinase Inhibitors Treatment
Increased fibroblast activation protein expression is positively correlated with the dedifferentiation and aggressiveness of thyroid cancer. Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel treatment for patients with radioactive iodine refractory thyroid cancer and disease progression after first-line treatment. However, a major problem in the therapeutic use of 177Lu-DOTA-FAPI has been its short half-life and fast rate of clearance. This study was designed to evaluate the safety, tolerability, and maximum tolerated dose of a long-lasting radiolabeled fibroblast activation protein inhibitor 177Lu-DOTA-EB-FAPI in mRAIR-TC patients with PD after TKIs treatment.
| Status | Recruiting |
| Enrollment | 20 |
| Est. completion date | June 15, 2025 |
| Est. primary completion date | June 15, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Ability to understand and willingness to sign a written informed consent document. 2. Age 18 and older 3. Confirmed unresectable or metastatic radioactive iodine refractory thyroid cancer with measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion > 1 cm or lymph node > 1.5 cm in short axis) 4. Progressive disease after TKIs treatment 5. Eastern Cooperative Oncology Group Performance Status = 3 6. Participant must have completed prior therapy at least 2 weeks (washout period) prior to 68Ga-FAPI-46 PET/CT scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved below Grade 2 or baseline. Completion of entry into 68Ga-FAPI-46 study and completion of scan 7. Hematologic parameters defined as: Absolute neutrophil count (ANC) = 1000 cells/mm3 Platelet count = 50,000/mm3 Hemoglobin = 8 g/dL Blood chemistry levels defined as: AST, ALT, alkaline phosphatase = 5 times upper limit of normal (ULN) Total bilirubin = 3 times ULN Creatinine = 3 times ULN Able to remain motionless for up to 30-60 minutes per scan Exclusion Criteria: 1. Participant on any chemical anticoagulant including antiplatelet agents (excluding ASA) 2. Participants with Class 3 or 4 NYHA Congestive Heart Failure 3. Clinically significant bleeding within two weeks prior to trial entry (e.g. gastrointestinal bleeding, intracranial bleeding) 4. Pregnant or lactating women 5. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to study day 1 or anticipated surgery within the subsequent 6 weeks 6. Has an additional active malignancy requiring therapy within the past 2 years 7. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy 8. Psychiatric illness/social situations that would interfere with compliance with study requirements 9. Cannot undergo PET/CT scanning because of weight limits (350 lbs) 10. INR>1.2; PTT>5 seconds above UNL |
| Country | Name | City | State |
|---|---|---|---|
| China | The First Affiliated Hospital of Xiamen University | Xiamen |
| Lead Sponsor | Collaborator |
|---|---|
| The First Affiliated Hospital of Xiamen University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence of treatment-related adverse events (safety and tolerability) | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. Dose-limiting toxicity was defined as any 177Lu-DOTA-EB-FAPI-related AE = grade 3 (G3). | From date of involvement until 6 weeks after the second treatment cycles | |
| Primary | To determine the maximum tolerated dose (MTD) | The MTD is the dose level below that which 2 out of 6 subjects in a cohort have DLT | From date of involvement until 6 weeks after the second treatment cycles | |
| Secondary | Objective response rate (ORR) | 68Ga-Fibroblast activation protein inhibitor 46 will be performed for efficacy evaluation by RECIST 1.1. Particularly, 68Ga-FAPI-46 will be performed at baseline, and 6 weeks after each treatment cycle. | baseline, 6 weeks after each treatment cycle | |
| Secondary | Dosimetry | Dosimetry, measured as absorbed dose in tumor and normal organs (Gy/GBq), was estimated in the first treatment cycle for each patient. | Dosimetry was estimated in the first treatment cycle for each patient |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04061980 -
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
| Active, not recruiting |
NCT03914300 -
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT00381641 -
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
|
Phase 2 | |
| Active, not recruiting |
NCT02152995 -
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
|
Phase 2 |